Neuroscientific Biopharmaceuticals Ltd (ASX:NSB)

34.0¢

right-arrow Created with Sketch. 0.05 (17.24%)
MCAP $41.60M
Last trade 10.37am 27/01/2022 20mins delayed

Latest Announcements

24/12/2021 Price SensitivePSNSBNeuroscientific Biopharmaceuticals Ltd
21/12/2021 Price SensitivePSNSBNeuroscientific Biopharmaceuticals Ltd
20/12/2021NSBNeuroscientific Biopharmaceuticals Ltd
13/12/2021NSBNeuroscientific Biopharmaceuticals Ltd
13/12/2021NSBNeuroscientific Biopharmaceuticals Ltd
13/12/2021NSBNeuroscientific Biopharmaceuticals Ltd
13/12/2021NSBNeuroscientific Biopharmaceuticals Ltd
08/12/2021NSBNeuroscientific Biopharmaceuticals Ltd

Company Overview

NeuroScientific Biopharmaceuticals Ltd is an Australia-based company, which develops peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with unmet medical demand. The company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinBTM is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

NSB in the news

NeuroScientific Biopharmaceuticals (NSB) reports positive results from off-target safety assessment of its…
NeuroScientific Biopharmaceuticals (NSB) records no adverse events during its non-clinical studies of…
NeuroScientific Biopharmaceuticals (NSB) receives Advance and Overseas Finding by AusIndustry for the…
NeuroScientific Biopharmaceuticals (NSB) says new biomarker data highlights the potential for its…

Search Previous Announcements